RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Daviddal, In retrospect, one of the aspects of the non-Ampakine in-licensing idea now seems a little suspicious to me, since Dr. Stoll first mentioned this idea out of the blue at a conf call/presentation last year. This was way before the FDA red-flagged CX-717, but probably not too long after Cortex likely saw the histo finding in the primate. Not knowing exactly what it was or what had caused it, but thinking that it might represent a possible major problem down the road, perhaps that prompted Dr. Stoll to start thinking about diversifying into a completely different non-Ampkaine area, just in case. While that may or may not have been the main reason for his interest in a non-Ampakine in-license, the desire to proactively diversify Cortex's drug development was in retrospect not a bad idea.

I personally think Dr. Stoll has done a fine job overall. With extremely limited funds, he had little choice but to put all the eggs in the CX-717 basket and then roll the dice. He rolled many successful passes with CX-717 before hitting trouble. I really thought we were in the clear with CX-717 safety-wise. I don't think we can really blame Stoll for the current situation, since it just boils down to a lead compound running into trouble, and that's the risks one takes with microcap bio stocks.